Compare IDEXX Laboratories, Inc. (IDXX) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Workday Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Workday Inc trades at $186.7 (market cap $45.26B). The key difference: IDEXX Laboratories, Inc. and Workday Inc are close in size by market cap, and Workday Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Workday Inc for 38 Days on average.
| IDXX | WDAY | |
|---|---|---|
Market Cap | $40.43B | $45.26B |
Volume | 692,164 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $766.68 | $245.67 |
52-Week Low | $504.70 | $112.55 |
Typical Hold Time | 46 Days | 38 Days |
Enterprise Value | $41.32B | $45.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Workday (WDAY) trades at $186.59, up 1.26% on the day, with a neutral technical signal and key support at $185. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.74. Revenue grew to $8.45B in 2025, and net income margin improved to 12.32%. Recent news includes expansion into the UAE and AI product launches, alongside a 2.5% headcount reduction for strategic realignment.
WDAY presents a mixed outlook: analyst consensus is a Buy with a $202.92 price target, signaling upside potential driven by AI integration and revenue growth. However, risks include execution challenges from restructuring, competitive pressures, and a high P/E ratio of 38.25. Investors should weigh strong fundamentals against near-term volatility and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
